Credit: Washington University in St. Louis.
New research led by Washington University School of Medicine in St. Louis shows that patients with acute myeloid leukemia (AML) whose cancer cells carry TP53 mutations — a feature that correlates with an extremely poor prognosis — may live longer if they are treated with decitabine, a less intensive chemotherapy drug. The study's first author, John Welch, MD, PhD, is pictured with Phillip Houghton, who is being treated for AML.